Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
NCT04918147Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in immunoglobulin G4-related disease (IgG4-RD), sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2021; status: terminated.
02
Drugs
elotuzumab
03
Conditions
immunoglobulin G4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT04918147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918147.